Q316 results highlighted a challenging quarter despite being broadly in line with company guidance (sales of €2.9m and an EBITDA loss of €1.8m). However, US sales were above company expectations (Q3: €0.7m, 9M: €2.0m) and are indicative that the initiatives put in place to drive sales in more established markets are beginning to prove fruitful. aap Implantate will need a solid Q4 to deliver on its FY16 revenue guidance, which it now expects to be at the lower end (€13
21 Nov 2016
Progression of LOQTEQ portfolio
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Progression of LOQTEQ portfolio
aap Implantate AG (AAQ1:ETR) | 0 0 5.5% | Mkt Cap: 50.5m
- Published:
21 Nov 2016 -
Author:
Dr Linda Pomeroy -
Pages:
2
Q316 results highlighted a challenging quarter despite being broadly in line with company guidance (sales of €2.9m and an EBITDA loss of €1.8m). However, US sales were above company expectations (Q3: €0.7m, 9M: €2.0m) and are indicative that the initiatives put in place to drive sales in more established markets are beginning to prove fruitful. aap Implantate will need a solid Q4 to deliver on its FY16 revenue guidance, which it now expects to be at the lower end (€13